WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (Nasdaq:INCY) announces the appointment of Edmund P. Harrigan, M.D., as a new member of the Board of Directors, effective December 16, 2019.
“We are delighted to welcome Edmund to Incyte. His extensive leadership experience in a variety of important areas including Clinical, Regulatory and Business Development will be instrumental as we continue to develop and commercialize innovative medicines for serious unmet medical conditions,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We look forward to benefiting from his valuable experience and further strengthening Incyte’s leadership.”
“It is an exciting time to be joining Incyte as the company strives to advance clinical candidates from its diverse portfolio,” said Dr. Harrigan. “I look forward working closely with the team to deliver on the company’s commitment to improving the lives of patients worldwide and building sustainable value for stakeholders.”
Dr. Harrigan served in various senior roles at Pfizer, Inc., including Senior Vice President of Worldwide Safety and Regulatory from 2012 until his retirement in 2015. Dr. Harrigan’s previous executive leadership roles at Pfizer included Senior Vice President, Head of Worldwide Business Development; Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance; and Vice President, Head of Neuroscience and Ophthalmology. In addition, he has served in senior leadership positions at Karuna Pharmaceuticals, Inc., Sepracor Inc. and Neurogen Corporation. Prior to joining the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. Dr. Harrigan earned his B.A. in Chemistry from St. Anselm College and M.D. from University of Massachusetts.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including without limitation statements regarding the Company’s efforts to advance its clinical pipeline, improve the lives of patients and build value for stakeholders contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks related to market competition, the results of and risks associated with research and development, risks and uncertainties associated with sales, marketing and distribution requirements, and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.
Contacts
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com